XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 0.7% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $1 | $1 | $1 |
| SG&A Expenses | $2 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $1 | $1 |
| Operating Income | -$2 | -$1 | -$1 | -$1 |
| % Margin | -481.6% | – | – | – |
| Other Income/Exp. Net | $1 | -$1 | -$0 | $1 |
| Pre-Tax Income | -$1 | -$2 | -$1 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$1 | $0 |
| % Margin | -227.7% | – | – | – |
| EPS | -0.15 | 0 | -0.25 | 0.08 |
| % Growth | – | 100% | -412.5% | – |
| EPS Diluted | -0.15 | 0 | -0.25 | 0.07 |
| Weighted Avg Shares Out | 7 | 5 | 5 | 5 |
| Weighted Avg Shares Out Dil | 7 | 5 | 5 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -206.2% | – | – | – |